Despite advances in treatment of bowel cancer, it remains the second most common cause of cancer death in the Western world. Use of drugs or nutritional supplements (chemoprevention) is an attractive strategy for prevention of bowel cancer in combination with other modalities such as population screening and endoscopic surveillance, particularly if the chemoprevention agent is safe, well tolerated and cost effective. This webinar describes existing evidence that omega-3 fatty acids have activity against bowel cancer. Recent completed and ongoing clinical trials of EPA for primary prevention of bowel cancer and prevention of metastatic disease are described. Current thinking about how omega-3 fatty acids might work against bowel cancer are also explained.
Date: July 9, 2015